Results 1 to 10 of about 5,494 (193)

Cost-Effectiveness of Aducanumab to Prevent Alzheimer's Disease Progression at Current List Price

Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022
Introduction An estimated 6 million Americans have Alzheimer's disease (AD). Aducanumab was recently approved by the Food and Drug Administration despite the lack of clinical effectiveness data.
Joshua A Barocas, Pranay Sinha
exaly   +3 more sources

A Real-World Pharmacovigilance Study of Adverse Drug Reactions Associated With Lecanemab and Aducanumab Based on WHO-VigiAccess and FAERS Databases [PDF]

Frontiers in Pharmacology
BackgroundLecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence.
Yunhan Zhao, Haoxiang Hu, Jianghai He
exaly   +4 more sources

Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies [PDF]

Alzheimers Dement
Abstract INTRODUCTION Anti‐amyloid antibody clinical trials with a high proportion of participants reaching treatment‐related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the double‐blind period was likewise associated with clinical benefit.
Pang M, Brothers H, O'Gorman J, Murphy J, Zabar Y, Lasky T, Shen C, Rubino I, Knopman D.   +8 more
europepmc   +2 more sources

Lifetime cost-effectiveness of lecanemab for early Alzheimer’s disease [PDF]

Frontiers in Public Health
IntroductionLecanemab is the second anti-amyloid-β monoclonal antibody to receive FDA approval for the treatment of early Alzheimer’s disease (AD), following aducanumab.
Xiangxiang Jiang, Gang Lv, Morgan E. Mendes, Jun Wu, Jing Yuan, Z. Kevin Lu   +5 more
doaj   +2 more sources

A prospective real‐world study of the efficacy and safety of aducanumab in China: Focus on early‐onset and autosomal dominant Alzheimer's disease [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Aducanumab is the first anti‐amyloid therapy used for Alzheimer's disease (AD) in China. METHODS This 12‐month, single‐center, real‐world study enrolled 12 participants with early AD receiving aducanumab 10 mg/kg every 4 weeks ...
Jinwen Xiao, Binyin Li, Biao Li, Jintao Wang, Ran Tang, Chao Gao, Xiangqian Che, Xiaomeng Xu, Shengdi Chen, Rujing Ren, Gang Wang   +10 more
doaj   +2 more sources

Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials [PDF]

Medical Sciences
Background: Anti-amyloid monoclonal antibodies represent the first disease-modifying therapeutic strategy targeting amyloid-β pathology in early Alzheimer’s disease (AD).
Albert Vamanu, Alexandra Mastaleru, Thomas Gabriel Schreiner, Gabriela Popescu, Adina Maria Roceanu, Andrei Ionut Cucu, Alexandru Patrascu, Georgiana-Anca Vulpoi, Robert-Valentin Bilcu, Romica Sebastian Cozma, Raluca Olariu, Cătălina Elena Bistriceanu, Roxana Covali, Dan Iulian Cuciureanu, Alin Ciubotaru   +14 more
doaj   +2 more sources

Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Monoclonal antibodies (mAbs) for Alzheimer's disease (AD) represent major therapeutic advances, but their economic value is uncertain.
Tuyet Thao Nguyen, Bozhidar T. Chakalov, Megan Van Noord, Charles DeCarli, Jeffrey S. Hoch   +4 more
doaj   +2 more sources

Increased risk of infusion‐related reactions switching between monoclonal antibodies for Alzheimer's disease: A case series [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Monoclonal antibodies (mAbs) targeting amyloid plaques are increasingly used in early Alzheimer's disease (AD). Infusion‐related reactions (IRRs) are recognized class effects, yet little is known about their occurrence when switching between
Ganesh Gopalakrishna, Cristina Tandoc, Pallavi Joshi   +2 more
doaj   +2 more sources

An insider's perspective on FDA approval of aducanumab

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023
Introduction Aducanumab was approved in 2021 by the US Food and Drug Administration (FDA) under the accelerated approval pathway. Since then, there have been many misconceptions about the approval decision despite multiple publications from the FDA to ...
Yaning Wang
doaj   +1 more source

Aducanumab: A new hope in Alzheimer's disease

Health Sciences Review, 2022
Alzheimer's disease is an insidious, slowly progressive neurodegenerative disease in aged people and the most prevalent form of dementia, characterized by loss of memory, behavioral changes, cognitive deterioration, and loss of functional abilities that ...
Rouchan Ali, Ghanshyam Das Gupta, Pooja A. Chawla   +2 more
doaj   +1 more source